Profilo
Edward Woenker has a current job as a Director at Novilytic LLC.
Posizioni attive di Edward Woenker
Società | Posizione | Inizio |
---|---|---|
Novilytic LLC
Novilytic LLC Medical/Nursing ServicesHealth Services Novilytic LLC is a private company that focuses on the pharmaceutical bioreactor market. The company supply kits that enable molecular recognition and quantification, which were developed and validated in collaboration with pharmaceutical pilot partners and customers. The company is based in West Lafayette, IN. Novilytic has worked on a number of SBIR grants through the National Institute of Health and its associated institutes. The company is backed by more than 10 patents (and two pending), partnerships with multiple analytical instrument companies, 2 pharmaceutical consortiums, and analytical science universities. The company's technology helps ensure quality and consistency by recognizing molecular structure early and often, which saves time and reduces purification costs. The CEO of the company is Paul C. Dreier. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Novilytic LLC
Novilytic LLC Medical/Nursing ServicesHealth Services Novilytic LLC is a private company that focuses on the pharmaceutical bioreactor market. The company supply kits that enable molecular recognition and quantification, which were developed and validated in collaboration with pharmaceutical pilot partners and customers. The company is based in West Lafayette, IN. Novilytic has worked on a number of SBIR grants through the National Institute of Health and its associated institutes. The company is backed by more than 10 patents (and two pending), partnerships with multiple analytical instrument companies, 2 pharmaceutical consortiums, and analytical science universities. The company's technology helps ensure quality and consistency by recognizing molecular structure early and often, which saves time and reduces purification costs. The CEO of the company is Paul C. Dreier. | Health Services |
- Borsa valori
- Insiders
- Edward Woenker